Nivolumab

Tyrosine kinase inhibitor-sensitive genomic aberrations, unresected tumors and not smoking were associated with increased treatment failure in non-small cell lung cancer, according to a presentation at the virtual ASCO annual meeting.

A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting.

The addition of nivolumab to neoadjuvant chemotherapy appeared safe and did not impact timing or feasibility of surgery among patients with resectable non-small cell lung cancer, according to results of the phase 3 CheckMate 816 trial.

Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large subset of patients with muscle-invasive bladder cancer, according to phase 2 study results.

The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy alone among patients with previously untreated advanced esophageal squamous cell carcinoma, according to phase 3 study findings.

The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer.

The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with advanced melanoma, according to results of the phase 2/phase 3 RELATIVITY-047 study presented at the virtual ASCO Annual Meeting.

Last week, an FDA panel voted against maintaining a gastric cancer indication for pembrolizumab and a hepatocellular carcinoma indication for nivolumab. It was the top story in hematology/oncology.

The FDA granted priority review to nivolumab for adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, according to the agent’s manufacturer.

The addition of nivolumab to neoadjuvant chemotherapy led to a significantly higher pathologic complete response rate among patients with resectable non-small cell lung cancer, according to results of a randomized phase 3 trial.